GlassScriptPhysician profile
Sherri G Martin
NPI 1780641456
$2,074.95
in general payments reported to CMS, 2019-2025
25 companies · $219 in 2025
The $219 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $201 · 2021: $273 · 2022: $304 · 2023: $406 · 2024: $401 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $314.22 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $288.94 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Cranial Technologies, INC | $236.93 | 2019-2025 | Doc Band |
| Sobi, INC | $168.03 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $160.73 | 2019-2024 | Vaxneuvance, Gardasil 9, Proquad |
| Supernus Pharmaceuticals, INC. | $152.35 | 2021-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $107.51 | 2019-2023 | Dyanavel Xr |
| Pfizer INC. | $98.12 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $88.82 | 2024-2025 | |
| Sanofi Pasteur INC. | $75.28 | 2019-2025 | |
| Kaleo, INC. | $74.04 | 2019-2024 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $61.70 | 2022-2023 | Flumist Quadrivalent |
| Adlon Therapeutics L.P. | $39.52 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.84 | 2021 | |
| Seqirus USA INC | $22.81 | 2025 | Flucelvax |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.88 | 2019 | |
| Noven Therapeutics, LLC | $17.73 | 2024 | Xelstrym |
| Abbott Laboratories | $17.05 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $16.07 | 2025 | Neffy |
| Shire North American Group INC | $15.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.98 | 2024 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $15.73 | 2022 | |
| Abbvie INC. | $14.92 | 2022 | |
| Genentech USA, INC. | $11.44 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.